Core Scientific (CORZ) Cash from Financing Activities (2021 - 2026)

Core Scientific (CORZ) has 6 years of Cash from Financing Activities data on file, last reported at $971.4 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 23239.16% year-over-year to $971.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $912.5 million (up 19.9% YoY) and the FY2025 annual result came in at -$63.1 million, down 107.7% from the prior year.
• Cash from Financing Activities improved to $971.4 million in Q1 2026 per CORZ's latest filing, from -$21.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $971.4 million in Q1 2026, with the low at -$45.1 million in Q3 2022.
• Average Cash from Financing Activities over 5 years is $117.0 million, with a median of -$4.2 million recorded in 2025.
• Year-over-year, Cash from Financing Activities tumbled 148.04% in 2023 and surged 23239.16% in 2026.
• Core Scientific's Cash from Financing Activities stood at $38.1 million in 2022, then plunged by 148.04% to -$18.3 million in 2023, then jumped by 3369.23% to $598.2 million in 2024, then sank by 103.65% to -$21.8 million in 2025, then surged by 4554.25% to $971.4 million in 2026.
• Business Quant data shows CORZ's Cash from Financing Activities at $971.4 million in Q1 2026, -$21.8 million in Q4 2025, and -$5.3 million in Q3 2025.